Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab

Sánchez-Montalvà, Adrián; Sellarès-Nadal, Júlia; Espinosa-Pereiro, Juan; Fernández-Hidalgo, Núria; Pérez‐Hoyos, S.; Salvador, Fernando; Durà, Xavier; Miarons, Marta; Antón, Andrés; Eremiev, Simeon; Sempere-González, Abiu; Monforte-Pallares, Arnau; Bosch-Nicolau, Pau; Augustín, Salvador; Sampol, Júlia; Guillén‐Del‐Castillo, Alfredo; Almirante, Benito

doi:10.1016/j.medcle.2021.06.023

Cited by 1 publication

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multicenter randomized open-label phase 2 trial in COVID-19 revealed that a multiple combination of an injectable of IFN beta-1b with LPV-RTV and ribavirin could reduce virus shedding and hospital stay. 283,284 However, Su and Jiang declared that the role of IFN in the pathogenesis of SARS-CoV-2 is suspicious and may enhance the expression of the ACE2 receptor. 285 On July 20, the British pharmaceutical company Synairgen announced that an inhaled form of IFN called SNG001 reduced the risk of severe Covid 19 infection in infected patients in a small clinical trial.…”

Section: Interferonsmentioning

confidence: 99%

“…The efficacy of IFN therapy was investigated in the SARS‐CoV and MERS‐CoV pandemic. A multicenter randomized open‐label phase 2 trial in COVID‐19 revealed that a multiple combination of an injectable of IFN beta‐1b with LPV‐RTV and ribavirin could reduce virus shedding and hospital stay 283,284 . However, Su and Jiang declared that the role of IFN in the pathogenesis of SARS‐CoV‐2 is suspicious and may enhance the expression of the ACE2 receptor 285 .…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19: A systematic review and update on prevention, diagnosis, and treatment

Aliabadi

Eivazzadeh‐Keihan

Parikhani

et al. 2022

MedComm

View full text Add to dashboard Cite

Since the rapid onset of the COVID‐19 or SARS‐CoV‐2 pandemic in the world in 2019, extensive studies have been conducted to unveil the behavior and emission pattern of the virus in order to determine the best ways to diagnosis of virus and thereof formulate effective drugs or vaccines to combat the disease. The emergence of novel diagnostic and therapeutic techniques considering the multiplicity of reports from one side and contradictions in assessments from the other side necessitates instantaneous updates on the progress of clinical investigations. There is also growing public anxiety from time to time mutation of COVID‐19, as reflected in considerable mortality and transmission, respectively, from delta and Omicron variants. We comprehensively review and summarize different aspects of prevention, diagnosis, and treatment of COVID‐19. First, biological characteristics of COVID‐19 were explained from diagnosis standpoint. Thereafter, the preclinical animal models of COVID‐19 were discussed to frame the symptoms and clinical effects of COVID‐19 from patient to patient with treatment strategies and in‐silico/computational biology. Finally, the opportunities and challenges of nanoscience/nanotechnology in identification, diagnosis, and treatment of COVID‐19 were discussed. This review covers almost all SARS‐CoV‐2‐related topics extensively to deepen the understanding of the latest achievements (last updated on January 11, 2022).

show abstract

Section: Interferonsmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%